Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The American Journal of Pathology|May 1, 1992
Characterization of the ELSV transgenic mouse model of pancreatic carcinoma. Histologic type of large and small tumorsS Glasner, V Memoli, D S Longnecker
The Yale Journal of Biology and Medicine|September 1, 1992
Recent results in animal models of pancreatic carcinoma: histogenesis of tumorsD S Longnecker, V Memoli, O S Pettengill
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 22, 1998
The combination of in situ hybridization and immunohistochemical analysis: an evaluation of Her2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epitheliumN Ratcliffe, W Wells, K Wheeler, et al.
Cancer|September 1, 1976
Direct immunoperoxidase staining for Regan isoenzyme of alkaline phosphatase in human tumor tissuesH Miyayama, G J Doellgast, V Memoli, et al.
Environmental Pollution (Barking, Essex : 1987)|June 13, 2022
Un-biodegradable and biodegradable plastic sheets modify the soil properties after six months since their applicationsG Santini, S Acconcia, M Napoletano, et al.
Breast Cancer Research and Treatment|June 1, 1995
Vasopressin gene related products are markers of human breast cancerW G North, S Pai, A Friedmann, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B studyS L Graziano, A Tatum, J E Herndon, et al.
Journal of Hematotherapy|October 1, 1995
Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
Lung Cancer (Amsterdam, Netherlands)|December 19, 1998
Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B studyS L Graziano, J A Kern, J E Herndon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1995
Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neuF H Valone, P A Kaufman, P M Guyre, et al.
Pageof 1